<DOC>
	<DOCNO>NCT01575873</DOCNO>
	<brief_summary>This study conduct patient take glucocorticoid treatment various disease . It 2-year study compare effect denosumab risedronate .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Denosumab Compared With Risedronate Individuals Taking Glucocorticoids</brief_title>
	<detailed_description>This 2-year study compare effect denosumab risedronate people take glucocorticoid therapy . The study look bone mineral density ( BMD ) spine hip two year treatment . Other endpoint include change wrist characteristic measure QCT , satisfaction treatment , effect biochemical marker bone turnover ( blood test measure bone health ) , fracture rate , effect bone histology ( characteristic bone study microscope ) .</detailed_description>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Men woman 18 year age old take glucocorticoid treatment . Men woman less 50 year age must fracture adult eligible . Men woman 50 year age old take glucocorticoid must meet protocolspecific BMD criterion . Use agent affect bone metabolism , use one biologic agent inflammatory disease , history bone disease ( except osteoporosis ) , low vitamin D level ( one enter trial vitamin D level correct ) , abnormalities blood calcium , underactive overactive thyroid condition treat stable , Addison 's disease , abnormality parathyroid gland ( gland control blood calcium ) , currently pregnant plan pregnancy , currently breast feeding , criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GIOP , Glucocorticoid , osteporosis , denosumab , BMD , Bone Mineral Density</keyword>
</DOC>